Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2024 | $46.00 → $33.00 | Outperform | Leerink Partners |
| 12/8/2023 | $41.00 | Overweight | Wells Fargo |
| 5/18/2023 | $48.00 | Buy | Canaccord Genuity |
| 4/13/2023 | $44.00 | Outperform | Robert W. Baird |
| 12/14/2022 | $33.00 | Buy | Stifel |
| 12/7/2022 | $42.00 | Overweight | JP Morgan |
| 9/1/2022 | $36.00 | Buy | Citigroup |
| 7/20/2022 | $33.00 | Outperform | SVB Leerink |
SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, process optimization and manufacturing experience across multiple drug modalities, including small molecules. In this role, Dr. Imbert will lead chemistry, manufacturing and control (CMC)-related acti
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company's global medical affairs activities including scientific communications and patient advocacy. "Gary brings deep global medical affairs leadership and strategic expertise in supporting successful and orphan disease
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced
Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced it will host a conference call and webcast on Tuesday, September 26, 2023 at 8:00 a.m. ET | 5:00 a.m. PT to discuss the interim results from the INTEGRIS-PSC Phase 2a trial. Members of Pliant's management will be joined by Gideon Hirschfield, FRCP, Ph.D., Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto and a principal investigator in the INTEGRIS-PSC trial. The conference call will be simultaneously webcast online and will be accessible from the Events & Presentation section of Pliant's website. The live audio of the conference call c
Leerink Partners resumed coverage of Pliant Therapeutics with a rating of Outperform and set a new price target of $33.00 from $46.00 previously
Wells Fargo initiated coverage of Pliant Therapeutics with a rating of Overweight and set a new price target of $41.00
Canaccord Genuity initiated coverage of Pliant Therapeutics with a rating of Buy and set a new price target of $48.00
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of common stock upon vesting to Delphine Imbert, Ph.D., the Company's newly appointed Chief Technical Officer, as a material inducement to her employment. The stock options that were granted are subject to an exercise price of $11.07 per share, which is equal to the closing price of the Company's common stock on January 21, 2025, and will vest over 4 years, with 25% of the shares underlying the employee's option vesting on the one-year anniversary of the grant date and the remai
Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, process optimization and manufacturing experience across multiple drug modalities, including small molecules. In this role, Dr. Imbert will lead chemistry, manufacturing and control (CMC)-related acti
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 1:30 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of Pliant's website at www.PliantRx.com. The replay of this webcast will be archived for 30 days following the conclusion of the event. About Pliant Therapeutics, Inc. Pliant Therapeutics is a late-stage biopharm
10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)